Shanghai-based ZAI Lab in-licenses autoimmune candidate from UCB

Shanghai-based biotech ZAI Lab has in-licensed global rights to a first-in-class monoclonal antibody aimed at treating autoimmune and other inflammatory diseases from Belgium's UCB, the company said in a press release. ZAI Lab said the candidate is deemed ready for Investigational New Drug-enabling studies and is expected to enter clinical Phase I in 2016. Initial indications are aimed at graft-versus-host disease and inflammatory bowel disease, ZAI Lab CEO Samantha Du said in the statement. Story

Suggested Articles

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.

AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.